German pharmaceutical giant Bayer said it’s facing a double hit from a higher legal bill for claims relating to weed killer Roundup and €9.25 billion ($10.8 billion) in impairments on Monsanto-related agriculture businesses. According to the company, the write-downs were driven by weaker demand from farmers due to low biofuel prices and an increase of about $750 million in the costs of settlement terms with US plaintiffs over Roundup. As a result, the losses before interest and tax amounted to €9.4 billion ($10.9 billion) in the third quarter. “The impact of the (coronavirus) pandemic is placing additional strain on our Crop Science Division. We are also facing negative currency effects,” Chief Financial Officer Wolfgang Nickl said. Nickl explained that a massive depreciation of the Brazilian real was weighing heavily on the firm’s business in the world’s second-largest agricultural market.